Table 2.

Studies on Prevalence of NAFLD in PCOS

Size		Diagnostic Criteria for PCOS	Diagnostic Basis for NAFLD	Prevalence (%)		Region	Author, Year, and Reference
PCOS	Control			PCOS	Control
200	-	NIH	ALT	14.50	-	U.S.A	Setji, 200618
88	-	NIH	Ultrasonography	54.50	-	U.S.A	Gambarin-Gelwan, 200619
41	31	Rotterdam	Ultrasonography	41.50	19.40	Chile	Cerda, 200720
			ALT	39.00	3.20
57	60	AES	Ultrasonography	36.80	20.00	Greece	Vassilatou, 201021
			ALT	22.80	3.30
192	73	AES	LIFL	34.00	6.90	Germany	Tan, 201022
			CK18-M30	27.60	1.40
34	32	Rotterdam	Liver biopsy	44.00	20.80	U.S.A	Hossain, 201123
45	32	Rotterdam	Ultrasonography	73.30	46.70	Brazil	Zueff, 201224
54	55	Rotterdam	Ultrasonography	66.70	25.40	India	Karoli, 201325
			ALT	31.40	7.30
602	588	Rotterdam	Ultrasonography	32.90	18.50	China	Qu, 201326
184	125	Rotterdam	Ultrasonography	57.60	49.60	Poland	Bohdanowicz-Pawlak, 201427
103	34	AES	Ultrasonography	23.80	3.30	Brazil	Romanowski, 201528
600	125	Rotterdam	LFS	50.60	34.00	Greece	Macut, 201629
400	100	Rotterdam	Ultrasonography	56.25	30.80	China	Cai, 201730
75	75	Rotterdam	Ultrasonography	38.70	18.70	Iran	Mehrabian, 201731
202	101	Rotterdam	HSI	68.80	33.30	Italy	Petta, 201732
188	65	Rotterdam	Ultrasonography	44.68	24.62	China	Zhang, 201833
60	-	Rotterdam	Ultrasonography	38.30	-	India	Harsha Varma, 201934
98	98	Rotterdam	CAP	69.30	34.60	Mexico	Salva-Pastor, 202035
70	60	Rotterdam	Ultrasonography	38.57	6.67	India	Chakraborty, 202036
87	40	Rotterdam	Ultrasonography	77.00	52.50	Brasil	Taranto, 202037
101	-	Rotterdam	CAP	39.60	-	Canada	Shengir, 202038

Abbreviations: PCOS, polycystic ovary syndrome; NAFLD, nonalcoholic fatty liver disease; NIH, National Institutes of Health; AES, androgen excess society; U.S.A, United States of America; ALT, alanine aminotransferase; LIFL, liver injury implicating fatty liver; CK18-M30, cytokeratin 18-M30; LFS, liver fat score; HSI, hepatic steatosis index; CAP, controlled attenuation parameter.